Key Inclusion Criteria:  Individuals with pathologically documented evidence of Stage IV non-small cell lung Cancer (NSCLC) disease at the time of enrollment Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) as per RECIST Version 1.1 criteria by investigator No prior systemic treatment for metastatic NSCLC Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 Adequate hematologic counts Adequate hepatic function  Key Exclusion Criteria:  Mixed SCLC and NSCLC histology Active second malignancy NSCLC that is eligible for definitive local therapy alone Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy Has an active autoimmune disease that has required systemic treatment in past 2 years Has had an allogenic tissue/solid organ transplant. Has severe (≥ Grade 3) hypersensitivity to SG, pembrolizumab, carboplatin, or cisplatin, their metabolites, or formulation excipient Has received radiation therapy to the lung Individuals may not have received systemic anticancer treatment within the previous 6 months Is currently participating in or has participated in a study of an investigational agent Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses Known active central nervous system (CNS) metastases History of cardiac disease Active chronic inflammatory bowel disease Active serious infection requiring antibiotics Active or chronic hepatitis B infection Positive hepatitis C antibody Positive serum pregnancy test or women who are lactating  Note: Other protocol defined Inclusion/Exclusion criteria may apply.